Investor Presentation Q1 2023

11 Investor presentation First three months of 2023 Novo NordiskⓇ PIONEER PLUS achieved its primary endpoint and demonstrated statistically significant HbA1c reduction vs oral sema 14 mg Oral semaglutide 25 mg and 50 mg vs 14 mg in subjects with T2D Oral semaglutide 50 mg R Oral semaglutide 25 mg 1:1:1 Oral semaglutide 14 mg 68 weeks 5 weeks follow-up Inclusion criteria (1,606 participants): Primary endpoint: Change from baseline to week 52 in HbA1c Secondary endpoint: . Type 2 Diabetes • HbA1c 8.0 - 10.5% . Change from baseline to week 52 in body weight BMI ≥25 kg/m² . Stable dose of 1-3 OADS *DPP-4i terminated at randomization (metformin, SU, SGLT-2i or DPP-4i*) Change from baseline (%) Headline trial results Change in HbA1c Change in body weight Mean baseline HbA1c: 9.0% Mean baseline body weight: 96.4 kg -1.5% -1.9%* -2.2%* Change from baseline (kg) -4.5 -7.0* -9.2* All doses of oral semaglutide appeared to have safe and well-tolerated profile Oral semaglutide 14 mg Oral semaglutide 50mg Oral semaglutide 25mg T2D: Type 2 diabetes; HbA1c: Glycated haemoglobin; BMI: Body Mass Index; OADs: Oral antidiabetic drugs; SU: Sulfonylurea; SGLT-2i; Sodium-glucose cotransporter-2 inhibitors; DPP-4i: dipeptidyl peptidase-4 inhibitors Note: Trial product estimands shown; Trial objective: To compare the safety and efficacy of 25 and 50 mg oral semaglutide with 14 mg oral semaglutide once daily in people with type 2 diabetes

View entire presentation